Hydromorphone

CHEMBL398707 Phase 4 承認済み Small molecule
Half-Life
2-3 hours
Bioavailability
Protein Binding
Molecular Weight
285.3 g/mol
LogP
1.8
Phase
4

A potent opioid analgesic used to treat moderate to severe pain, including cancer pain and postoperative pain, by binding to opioid receptors in the central nervous system to reduce pain perception. It is several times more potent than morphine and is available in oral, intravenous, and subcutaneous formulations. Careful dose titration and monitoring for respiratory depression are essential during use.

分子量

285.3380 g/mol

LogP

1.80

TPSA

49.80 Ų

リピンスキーの五則

適合

治療領域

薬物分類

作用機序

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

Pharmacokinetics (PK)

Half-Life 2-3 hours

Pharmacodynamics (PD)

機序

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5

InChI

InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

Molecular Formula

C17H19NO3

HBD / HBA

1 / 4

回転可能結合数

0

重原子数

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A potent opioid analgesic used to treat moderate to severe pain, including cancer pain and postoperative pain, by binding to opioid receptors in the central nervous system to reduce pain perception. It is several times more potent than morphine and is available in oral, intravenous, and subcutaneous formulations. Careful dose titration and monitoring for respiratory depression are essential during use.

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

Key pharmacokinetic parameters for Hydromorphone: Half-life: 2-3 hours.

Yes, Hydromorphone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL398707. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5284570. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.